J&J(US:JNJ) Benzinga·2025-09-25 19:01Core Insights - Financial giants are showing a bullish sentiment towards Johnson & Johnson, with 58% of traders being bullish and only 23% bearish, indicating strong market interest [1] - The projected price targets for Johnson & Johnson range from $145.0 to $190.0, suggesting significant upside potential based on recent trading activity [2] - Analysts have set a consensus target price of $203.0, with one analyst from JP Morgan maintaining a Neutral rating and another from Guggenheim upgrading to Buy with a target of $206 [11][12] Options Activity - A total of 17 unusual trades were identified, with 14 calls valued at $935,177 and 3 puts valued at $283,763, reflecting a preference for bullish positions [1] - The volume and open interest data for options indicate heightened liquidity and interest in the $145.0 to $190.0 strike price range over the past 30 days [3][4] - Noteworthy options activity includes various trades with significant total trade prices, such as a bullish call trade with a total price of $185.4K at a strike price of $180.00 [8] Company Overview - Johnson & Johnson is the largest and most diverse healthcare firm globally, focusing on innovative medicine and medtech after divesting its consumer business in 2023 [9] - The drug division is concentrating on three main therapeutic areas: immunology, oncology, and neurology, with over half of its revenue generated in the United States [9] - Current trading volume for Johnson & Johnson is 4,449,853, with the stock price at $177.32, reflecting a slight increase of 0.36% [14]